Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Arrowhead Pharmaceuticals Inc (ARWR)  
$25.00 0.04 (0.16%) as of 4:30 Thu 5/16


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 102,290,000
Market Cap: 2.56(B)
Last Volume: 372,414 Avg Vol: 371,384
52 Week Range: $21.2 - $40.08
Level I Sector: Industrials
Level II Sector: Diversified Services
Level III Sector: Business Services

Member Indexes:
    NASDAQ COMPOSITE     NASDAQ INDUSTRIAL

Rankings:
     
Insider 3 Months    : 7
Insider 6 Months    : 7
Insider 3/6 Months : 14.3
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of RNA chemistries and several modes of delivery, Co.'s therapies trigger the RNA interference (RNAi) mechanism to induce knockdown of target genes. Co. is focused on developing drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. Co.'s pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, and ARO-DUX4 for facioscapulohumeral muscular dystrophy.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 3,000 3,000 3,000 3,000
Total Buy Value $82,990 $82,990 $82,990 $82,990
Total People Bought 1 1 1 1
Total Buy Transactions 3 3 3 3
Total Shares Sold 47,799 265,716 376,284 581,100
Total Sell Value $1,617,715 $8,886,331 $12,105,321 $19,869,244
Total People Sold 3 10 10 11
Total Sell Transactions 3 20 26 36
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 361
  Page 11 of 15  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Obrien Patrick General Counsel   •       –      –    2019-01-18 4 AS $14.43 $1,038,960 D/D (72,000) 233,000     -
   Myszkowski Kenneth Allen Chief Financial Officer   •       –      –    2019-01-17 4 AS $14.55 $1,191,281 D/D (81,875) 305,607     -
   Given Bruce D Chief Operating Officer   •       –      –    2019-01-14 4 AS $14.40 $614,390 D/D (42,666) 1,068,356     -
   Given Bruce D Chief Operating Officer   •       –      –    2019-01-14 4 OE $2.62 $36,765 D/D 12,666 1,111,022     -
   Li Zhen Snr. VP, Chem and Non-Clin Dev   •       –      –    2019-01-14 4 AS $14.34 $580,770 D/D (40,500) 201,700     -
   Waddill William D. Director   –       •      –    2019-01-11 4 S $14.77 $125,545 D/D (8,500) 46,500     -
   Ferrari Mauro Director   –       •      –    2019-01-02 4 A $0.00 $0 D/D 3,429 19,656     -
   Myszkowski Kenneth Allen Chief Financial Officer   •       –      –    2019-01-02 4 AS $11.98 $99,829 D/D (8,333) 387,482     -
   Given Bruce D Chief Operating Officer   •       –      –    2019-01-02 4 AS $11.98 $239,600 D/D (20,000) 1,098,356     -
   Perry Michael S Director   –       •      –    2019-01-01 4 A $0.00 $0 D/D 36,000 221,000     -
   Given Douglas B Director   –       •      –    2019-01-01 4 A $0.00 $0 D/D 36,000 181,130     -
   Waddill William D. Director   –       •      –    2019-01-01 4 A $0.00 $0 D/D 30,000 55,000     -
   Li Zhen Snr. VP, Chem and Non-Clin Dev   •       –      –    2019-01-01 4 A $0.00 $0 D/D 75,000 242,200     -
   Myszkowski Kenneth Allen Chief Financial Officer   •       –      –    2019-01-01 4 A $0.00 $0 D/D 85,000 395,815     -
   Given Bruce D Chief Operating Officer   •       –      –    2019-01-01 4 A $0.00 $0 D/D 210,000 1,118,356     -
   Obrien Patrick General Counsel   •       –      –    2019-01-01 4 A $0.00 $0 D/D 70,000 305,000     -
   Anzalone Christopher Richard Chief Executive Officer   •       •      –    2019-01-01 4 A $0.00 $0 D/D 600,000 2,142,455     -
   Given Douglas B Director   –       •      –    2018-12-27 4 AS $12.00 $36,000 D/D (3,000) 145,130     -
   Anzalone Christopher Richard Chief Executive Officer   •       •      –    2018-12-19 4 AS $13.92 $1,252,800 D/D (90,000) 1,542,455     -
   Ferrari Mauro Director   –       •      –    2018-12-18 4 A $0.00 $0 D/D 3,459 16,227     -
   Anzalone Christopher Richard Chief Executive Officer   •       •      –    2018-12-12 4 AS $14.07 $1,266,300 D/D (90,000) 1,632,455     -
   Given Douglas B Director   –       •      –    2018-11-23 4 AS $12.74 $38,220 D/D (3,000) 148,130     -
   Anzalone Christopher Richard Chief Executive Officer   •       •      –    2018-11-09 4 AS $14.35 $1,172,705 D/D (81,500) 1,722,455     -
   Given Douglas B Director   –       •      –    2018-10-22 4 GD $0.00 $0 D/D 3,870 151,130     -
   Leone Peter Brian VP, Strategic Bus. Initiatives   •       –      –    2018-10-19 4 S $13.49 $1,769,038 D/D (131,137) 130,000     -
  361 Records found
  Previous  10  11  12  13  14  15   
  Page 11 of 15
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us